GET DAILY SIGNALSJazz Pharmaceuticals (JAZZ) Delivers Record Q3 Revenue Up 10% Year Over Year
Key Takeaways
- Jazz Pharmaceuticals reported record total revenue of $1.24 billion for the third quarter of 2026, up 10% year over year and above consensus estimates of roughly $1.20 billion.
- Reported (GAAP) earnings per share came in at a loss of $3.88, versus a consensus forecast for a profit of $6.30, driven by a one-time charge tied to the Actio Biosciences acquisition.
- Excluding the $754 million charge, adjusted (non-GAAP) earnings per share would have been about $7.15, reflecting stronger underlying operating performance.
- The company raised and narrowed its full-year 2026 revenue guidance to $4.775 billion to $4.85 billion, its second consecutive quarterly guidance increase.
- Growth was broad-based, led by Xywav, Epidiolex, and a fast-expanding oncology portfolio, including the early launch of Ziihera.
- For more detail, explore the company's Major News, Today's Price Move, Price Targets, and Forecast pages.
- You can also explore Trending AI Robots to see how AI-driven trading strategies are positioned across the market.
Earnings Context and Why It Matters
Jazz Pharmaceuticals is a biopharmaceutical company focused on neuroscience and oncology, with an established rare-sleep franchise and a growing oncology portfolio. Its third-quarter results matter because they test whether the company can keep growing revenue while the rare-sleep business faces emerging competition from orexin-2 receptor agonists and high-sodium generic oxybate products. The quarter also marked the first full look at the early commercial launch of Ziihera in HER2-positive gastric cancer, a key growth bet for the company. Investors were watching both the durability of Xywav demand and whether management would again raise its outlook — a signal of confidence in the commercial business heading into 2027. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Jazz reported record total revenue of $1.24 billion for the third quarter ended September 30, 2026, up 10% year over year and above the roughly $1.20 billion consensus estimate. Oncology revenue grew 35% year over year, helped by Zepzelca ($104 million, up 32%), the early launch of Ziihera ($21 million), and the continued uptake of Modeyso.
In the rare-sleep franchise, Xywav net product sales rose 12% to $483 million, with approximately 425 net patient additions during the quarter. Epidiolex contributed $295 million, supported by solid underlying demand.
Reported earnings per share (EPS) was a loss of $3.88, below the consensus forecast for a $6.30 profit. The shortfall was driven by a $754 million charge related to in-process research and development (IPR&D) from the completed acquisition of Actio Biosciences. Excluding that item, adjusted (non-GAAP) EPS would have been approximately $7.15.
Management raised full-year 2026 revenue guidance to $4.775 billion to $4.85 billion (implying roughly 13% growth at the midpoint) and lifted non-GAAP gross margin guidance to 90.5%–91.5%. The company ended the quarter with $2.9 billion in cash and investments and $5.6 billion in long-term debt, while generating $1.3 billion in operating cash flow over the first nine months of the year.
Market Reaction and Investor Sentiment
The initial market reaction was muted. Shares ended the regular session at $214.44, down about 0.7% from the prior close, before edging up roughly 0.3% to $215 in after-hours trading. That suggests investors largely looked past the headline EPS loss, which stemmed from a one-time acquisition-related charge rather than a deterioration in the underlying business. The modest move also indicates that much of the positive news — record revenue and another guidance increase — may have been anticipated ahead of the report. Sentiment remains supported by the durability of Xywav and the early traction of Ziihera, but investors are still weighing competitive risks in sleep medicine and oncology heading into 2027. From what I see, this measured response aligns with the strong underlying metrics.
Forward Outlook and Key Factors to Monitor
Following this report, several catalysts are worth watching. The company expects to present initial patient data for ABS-1230, a clinical-stage precision therapy targeting the KCNT1 ion channel in rare epilepsy, during the fourth quarter of 2026. That asset came with the Actio acquisition and represents a key pipeline bet in neuroscience.
In oncology, investors will be monitoring the trajectory of Ziihera's launch in HER2-positive gastric cancer. Management has indicated the product should become more meaningful to results in 2027 than in 2026. At the same time, Zepzelca could face a competitive headwind next year from Amgen's IMDELLTRA.
On the sleep side, the company is watching the introduction of orexin-2 receptor agonists, which could modestly slow new patient starts in some segments. Management has emphasized that Xywav's low-sodium profile and its role in treating disrupted nighttime sleep support its durability. Upcoming clinical readouts, including the ACTION trial for Modeyso in the first half of 2027 and top-line data from the EmpowHER-303 study in late 2027 or early 2028, round out the key items on the horizon. I’m watching this closely as these milestones could shape the stock’s path.
Exploring AI Tools in My Research
In my analysis of earnings reports like this one, I often turn to Tickeron’s AI Screener to quickly filter opportunities and compare performance across sectors. It helps me spot patterns in fundamentals and technical signals that might otherwise take hours to review manually. This tool has become a regular part of how I build context around quarterly results and identify related names worth tracking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JAZZ's RSI Indicator climbs out of oversold territory
The RSI Indicator for JAZZ moved out of oversold territory on October 29, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In 17 of the 25 cases the stock moved higher. This puts the odds of a move higher at 68%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on JAZZ as a result. In 60 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.
The Moving Average Convergence Divergence (MACD) for JAZZ just turned positive on October 29, 2026. Looking at past instances where JAZZ's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.
Following a +5.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where JAZZ advanced for three days, in 176 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
JAZZ may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JAZZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
The Aroon Indicator for JAZZ entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 38 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 50 (best 1 - 100 worst), indicating steady price growth. JAZZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.899) is normal, around the industry mean (3.104). P/E Ratio (14.099) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.941) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (3.407) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products
Industry Biotechnology
Advertisement